Registration open for ICTD 2026
International Clinical Trials Day 2026 - Stronger Together: Advanced therapy clinical trials without borders
International Clinical Trial Day 2026 will focus on Stronger Together: Advanced therapy clinical trials without borders. The 2026 edition of this international event will be co-hosted by ECRIN (European Clinical Research Infrastructure Network) and its Czech scientific partner CZECRIN (Czech Clinical Research Infrastructure Network) on May 20th, 2026. ICTD commemorates the start of the landmark clinical trial, led by James Lind on sailors with scurvy, 20 May 1747. Having laid the foundation for modern clinical research, ECRIN salutes this initiative by addressing a new topic in clinical research every year on or around this date.
ICTD brings together patients, health policy actors, health authorities, clinical researchers, health professionals and citizens from Europe and beyond to discuss issues related to multinational clinical studies. ICTD 2026 will be hosted by CZECRIN, in Prague, Czech Republic, and as a hybrid event it also will be broadcasted online. ICTD 2026 is free and open to all interested, pending available space.
Advanced therapy clinical trials without borders
Advanced Therapy Medicinal Products (ATMPs) represent a rapidly evolving area of clinical research, encompassing gene therapies, cell therapies, and tissue-engineered products designed to address diseases with high unmet medical need. Clinical research on ATMPs is characterised by complex trial designs, and unlike conventional drugs, it requires close integration of clinical protocols with GMP-compliant manufacturing, and long-term follow-up to monitor durability of effect and potential delayed risks. As a result, regulatory, ethical, and logistical considerations play a central role in ATMP clinical research and are increasingly complex when we want to work across borders.
Agenda
The day is broken down into 3 parts, the first of which is setting the scene where in Professor Gonzalo Calvo will discuss cross cutting challenges in ATMP clinical trials. This is followed by a case study highlighting the difficulties encountered when trying to expand advanced therapy studies beyond the national borders in Europe.
The majority of the day is then spent on the different stakeholder perspectives including patients, regulators, health technology assessment, sponsors, funders and investigators.
To close the day, we move from challenges to solutions, how do we improve. A high-level reflection on the European efforts is shared and then discussed in a panel session.
